DNA Therapy Slashes Bad Cholesterol by 50%

Researchers have developed a groundbreaking DNA-based therapy that significantly reduces "bad" cholesterol levels. In recent studies involving animal models, this new approach achieved an almost 50% decrease in LDL cholesterol without the side effects commonly associated with statin medications. The therapy's effectiveness stems from its ability to target and suppress the PCSK9 protein, which normally limits the liver's capacity to remove LDL cholesterol from the bloodstream.

This innovative treatment utilizes small DNA molecules, known as polypurine hairpins (PPRHs), designed to silence the gene responsible for PCSK9 production. Experiments with human liver cells demonstrated that a specific molecule, HpE12, reduced PCSK9 RNA by 74% and the protein itself by 87%. Further trials in mice showed a single injection of HpE12 lowered blood PCSK9 levels by approximately 50% and total cholesterol by nearly 47% within three days.

The mechanism behind this therapy involves enabling the liver to naturally enhance its cholesterol-clearing capabilities. Unlike statins, which inhibit cholesterol production, this DNA-based method allows the body to more effectively regulate and remove excess cholesterol. This targeted action may also reduce the risk of adverse effects like muscle pain and digestive issues often seen with statins. Researchers believe this therapy could offer a safer and potentially more adherent treatment option for managing high cholesterol.